ES-2 clones overexpressing KLK5, 10/5, 10/6, 5/6 made significantly fewer colonies in soft agar

ES-2 clones overexpressing KLK5, 10/5, 10/6, 5/6 made significantly fewer colonies in soft agar. quantitatively and qualitatively in their presentation of ascites, with both a reduced incidence of ascites and an absence of cellular aggregates within those ascites. The survival advantage conferred by KLK10 overexpression could be recapitulated with the exogenous administration of a recombinant KLK10. In conclusion, these findings indicate that KLK5, 6 and 10 may modulate the progression of ovarian cancer, and interact with each other to alter tumour pathophysiology. Furthermore, results support the putative ERBB role of KLK10 as a tumour suppressor and suggest it may hold therapeutic potential in ovarian cancer. == Introduction == The recently discovered tissue kallikreins are a family of secreted serine proteases encompassing 15 users (KLK1-15) whose genes (KLK1-15) are clustered in tandem on a 300 kb region on chromosome 19q13.4[1]. KLK proteins are detected in many biological fluids including blood, seminal plasma, sweat, saliva, cerebrospinal fluid, milk, and interstitial spaces where they can be activated and/or inactivated by enzymatic cleavage[2]. KLKs cleave a broad range of substrates including extracellular matrix (ECM) proteins, insulin-like growth factor binding proteins, protease-activated receptors (PAR), other kallikreins and even themselves[2]. Moreover, KLKs are often expressed in groups, such as KLK3, 4, 5, 6, 8, 10, 13 and 14 in the breast or KLK2, 3, 4, 5, 11, and 15 in the prostate[2]. These observations have led to the hypothesis that kallikreins can take action in a cascade to mediate their biological effects, also known as the KLK activome[3]. For example, preliminary evidence suggests that KLK5 may be an initiator of KLK cascades, capable of activating pro-KLK2, 3, 6, 7, 11, 12, 14, resulting in the degradation of ECM components of semen, and liquefaction[4]. Kallikreins have been implicated in a number of diseases such as Alzheimer’s and multiple sclerosis[5],[6], inflammatory bowel disease[7], arthritis[8], sepsis[9], diabetes[10], skin diseases[11]and cancer[12]. Because KLKs are secreted and readily detectable in biological fluids, they have emerged as potentially valuable biomarkers, particularly in cancer, where KLK3 (also known as prostate specific antigen) has proven to be useful for prostate cancer monitoring. Most KLK expression is usually under hormonal control, and the responsiveness of KLK2 and 3 Moexipril hydrochloride to androgens in prostate cancer cell lines[13], and KLK6 and 10 to estrogens in breast cancer cell lines is usually well documented[14],[15]. The pattern of expression of KLKs, as well as their hormonal regulation, suggests they may be involved in endocrine-related adenocarcinomas of the reproductive tract such as prostate, testis, breast, cervical, and ovarian cancers. Accumulating evidence suggests that at least 12 of the 15 kallikreins are upregulated in ovarian cancer. Of those, KLK4, 5, 6, 7, 10, and 15 are associated with unfavorable prognosis while the expression of KLK8, 9, 11, 13, and 14 is usually associated with a favorable prognosis[12]. This study focuses on KLK5, 6 and 10 which are frequently overexpressed in ovarian cancer and found in elevated levels in the ascites and serum of patients[16][18]. Notably, serum KLK6 and KLK10 are indicators of poor prognosis[19],[20], and high KLK6 is usually associated with shorter recurrence-free survival and lower overall survival[21]. High Moexipril hydrochloride levels of KLK10 in the serum are associated with advanced stage serous tumours with large residual disease and poor response to chemotherapy[22], while low levels of KLK10 in the tumour predict poor overall survival[23]. The histological subtypes of epithelial ovarian cancers, such Moexipril hydrochloride as serous, mucinous, endometroid, obvious cell and undifferentiated tumours may reflect distinct ontogenies and are becoming increasingly important in tailoring treatment[24]. Moexipril hydrochloride The expression of KLKs is usually remarkably similar across histological subtypes. For example, all subtypes express KLK6, with perhaps a slightly higher proportion of clear cell tumours that display strong immunostaining for KLK6[21],[25]. Similarly, patients with tumours of each subtype have detectable levels of KLK10 in their cytosols, with a slight but significantly higher proportion of KLK10 high patients being of the serous subtype[26]. Finally, KLK5 expression appears to be more prevalent in serous and undifferentiated tumours[27],[28]. While little is known about the biological basis for the contribution of KLK5, 6 and 10 to ovarian cancer, the ability of KLK5 and 6 to cleave ECM proteins[4],[29], and activate PAR signaling[30], suggest that they are Moexipril hydrochloride directly implicated in various aspects of carcinogenesis. Degradation of ECM components may facilitate the detachment.